These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8943690)

  • 21. DT-diaphorase activity in normal and neoplastic human tissues; an indicator for sensitivity to bioreductive agents?
    Smitskamp-Wilms E; Giaccone G; Pinedo HM; van der Laan BF; Peters GJ
    Br J Cancer; 1995 Oct; 72(4):917-21. PubMed ID: 7547240
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Population pharmacokinetics and dynamics in phase II studies of the novel bioreductive alkylating cytotoxic indoloquinone EO9.
    Schellens JH; Dombernowsky P; Cassidy J; Epelbaum R; Dirix L; Cox EH; Wanders J; Calabresi F; Paridaens R; Monfardini S; Wolff J; Loos WJ; Verweij J; Pavlidis N; Hanauske AR;
    Anticancer Drugs; 2001 Aug; 12(7):583-90. PubMed ID: 11487714
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Paclitaxel and concurrent radiation therapy for locally advanced adenocarcinomas of the pancreas, stomach, and gastroesophageal junction.
    Safran H; Akerman P; Cioffi W; Gaissert H; Joseph P; King T; Hesketh PJ; Wanebo H
    Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):53-7. PubMed ID: 10210540
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacological and biochemical determinants of the antitumour activity of the indoloquinone EO9.
    Cummings J; Spanswick VJ; Gardiner J; Ritchie A; Smyth JF
    Biochem Pharmacol; 1998 Feb; 55(3):253-60. PubMed ID: 9484790
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics, distribution, and metabolism of the novel bioreductive alkylating indoloquinone EO9 in rodents.
    Workman P; Binger M; Kooistra KL
    Int J Radiat Oncol Biol Phys; 1992; 22(4):713-6. PubMed ID: 1544843
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9.
    Fitzsimmons SA; Workman P; Grever M; Paull K; Camalier R; Lewis AD
    J Natl Cancer Inst; 1996 Mar; 88(5):259-69. PubMed ID: 8614004
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bioreductive drugs as post-irradiation sensitizers: comparison of dual function agents with SR 4233 and the mitomycin C analogue EO9.
    Adams GE; Stratford IJ; Edwards HS; Bremner JC; Cole S
    Int J Radiat Oncol Biol Phys; 1992; 22(4):717-20. PubMed ID: 1544844
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A weekly 24-h infusion of high-dose 5-fluorouracil (5-FU)+leucovorin and bi-weekly cisplatin (CDDP) was active and well tolerated in patients with non-colon digestive carcinomas.
    Caroli-Bosc FX; Van Laethem JL; Michel P; Gay F; Hendlisz A; Forget F; Bleiberg H
    Eur J Cancer; 2001 Oct; 37(15):1828-32. PubMed ID: 11576835
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of metastatic breast cancer with AZQ: a phase II trial.
    Martino S; Ratanatharathorn V; Samal BA; Singhakowinta A; Haas C
    Cancer Invest; 1988; 6(3):289-91. PubMed ID: 3167612
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The experimental development of bioreductive drugs and their role in cancer therapy.
    Workman P; Stratford IJ
    Cancer Metastasis Rev; 1993 Jun; 12(2):73-82. PubMed ID: 8375022
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemosensitivity to the indoloquinone EO9 is correlated with DT-diaphorase activity and its gene expression.
    Smitskamp-Wilms E; Peters GJ; Pinedo HM; van Ark-Otte J; Giaccone G
    Biochem Pharmacol; 1994 Apr; 47(8):1325-32. PubMed ID: 7514407
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Involvement of DT-diaphorase (EC 1.6.99.2) in the DNA cross-linking and sequence selectivity of the bioreductive anti-tumour agent EO9.
    Bailey SM; Wyatt MD; Friedlos F; Hartley JA; Knox RJ; Lewis AD; Workman P
    Br J Cancer; 1997; 76(12):1596-603. PubMed ID: 9413948
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacological approach towards the development of indolequinone bioreductive drugs based on the clinically inactive agent EO9.
    Loadman PM; Bibby MC; Phillips RM
    Br J Pharmacol; 2002 Nov; 137(5):701-9. PubMed ID: 12381684
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Targeted therapies in digestive oncology].
    Boutayeb S; Bensouda Y; Fadoulkhair Z; Bakkraoui K; Bachouchi M; Errihani H
    Pathol Biol (Paris); 2012 Aug; 60(4):264-8. PubMed ID: 22743093
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study.
    Gasparini G; Caffo O; Barni S; Frontini L; Testolin A; Guglielmi RB; Ambrosini G
    J Clin Oncol; 1994 Oct; 12(10):2094-101. PubMed ID: 7931479
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The autoxidation of the reduced forms of EO9.
    Butler J; Spanswick VJ; Cummings J
    Free Radic Res; 1996 Aug; 25(2):141-8. PubMed ID: 8885332
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EO9 (Apaziquone): from the clinic to the laboratory and back again.
    Phillips RM; Hendriks HR; Peters GJ;
    Br J Pharmacol; 2013 Jan; 168(1):11-8. PubMed ID: 22509926
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I/II pilot study of intravesical apaziquone (EO9) for superficial bladder cancer.
    Puri R; Palit V; Loadman PM; Flannigan M; Shah T; Choudry GA; Basu S; Double JA; Lenaz G; Chawla S; Beer M; Van Kalken C; de Boer R; Beijnen JH; Twelves CJ; Phillips RM
    J Urol; 2006 Oct; 176(4 Pt 1):1344-8. PubMed ID: 16952628
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical applications of quinone-containing alkylating agents.
    Begleiter A
    Front Biosci; 2000 Nov; 5():E153-71. PubMed ID: 11056078
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Provision for adverse effect of S-1 containing chemotherapy in patients with advanced digestive cancer--combination with superfine dispersed lentinan].
    Yagi M; Watanabe S; Yoshino S; Hazama S; Suga T; Nakazawa S
    Gan To Kagaku Ryoho; 2010 Mar; 37(3):457-62. PubMed ID: 20332683
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.